File downloaded on 2026-11-19
Source URL: https://medicines.health.europa.eu/veterinary/en/600000066162

Eurican piro

Not authorised

- Babesia canis, subsp. canis, strain BC 14-9, soluble parasite antigen

Product identification

Medicine name:
Eurican piro

Active substance:
Babesia canis, subsp. canis, strain BC 14-9, soluble parasite antigen

Target species:
Dog

Route of administration:
Subcutaneous use

Product details

Active substance and strength:
Babesia canis, subsp. canis, strain BC 14-9, soluble parasite antigen
160.00 antibody unit(s) / 1.00 millilitre(s)

Pharmaceutical form:
Lyophilisate for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AB

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Surrendered

Authorised in:
Netherlands

Package description:
Available only in Dutch
Available only in Dutch

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Legal basis not covered by Directive 2001/82/EC

Marketing authorisation holder:
Boehringer Ingelheim Animal Health Netherlands B.V.

Marketing authorisation date:
17/06/1999

Manufacturing sites for batch release:
Boehringer Ingelheim Animal Health France

Responsible authority:
Medicines Evaluation Board

Authorisation number:
REG NL 3654

Date of authorisation status change:

1/05/2023

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.